文献速递免疫规划

以Advax-CpG佐剂配制的伤寒蛋白荚膜基质疫苗候选物可在小鼠、兔和非人灵长类中诱导稳健且持久的抗伤寒Vi多糖抗体应答

A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates.
PubMed 文献 · Vaccine · 2022-06-22

Typhax是一种研究性伤寒疫苗候选物,由伤寒沙门菌Vi多糖非共价包埋于戊二醛催化交联的α-聚-L-赖氨酸与CRM197蛋白基质中组成。本研究探讨Advax-CpG佐剂能否克服多糖诱导的免疫抑制并提高Typhax免疫原性,结果显示在小鼠、兔和非人灵长类中均诱导高且持续的Vi IgG应答,且重复免疫可提升抗体水平。

要点

  • Advax-CpG佐剂化Typhax在小鼠、兔和非人灵长类中诱导高且持续的Vi IgG应答。
  • 在非人灵长类中,Advax-CpG佐剂化Typhax诱导的Vi IgG水平较商业Typhim Vi多糖疫苗最高高100倍。
  • CD4+ T细胞耗竭小鼠中高Vi抗体应答丧失,表明Typhax以T细胞依赖方式发挥作用。

核心结论

  • Advax-CpG佐剂化Typhax疫苗是提供针对伤寒的稳健且持久保护的高度有前景的候选疫苗。

研究设计与样本

  • 本研究为动物实验,在小鼠、兔和非人灵长类中评估Advax-CpG佐剂化Typhax的免疫原性。

主要发现

  • Advax-CpG佐剂化Typhax在小鼠、兔和非人灵长类中诱导高且持续的Vi IgG应答,且重复免疫可提升抗体水平。
  • CD4+ T细胞耗竭小鼠中高Vi抗体应答丧失,证实Typhax以T细胞依赖方式发挥作用。
  • 在非人灵长类中,Advax-CpG佐剂化Typhax诱导的Vi IgG水平较商业Typhim Vi多糖疫苗最高高100倍。
  • Typhax诱导高且持续的针对伤寒沙门菌的血清杀菌活性,即使在先前用纯多糖疫苗致敏的动物中也能刺激稳健的Vi IgG应答。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Typhax is an investigational typhoid fever vaccine candidate that is comprised of Vi polysaccharide from Salmonella enterica serovar typhi (S. Typhi) non-covalently entrapped in a glutaraldehyde catalyzed, cross-linked α-poly-L-lysine and CRM197 protein matrix. A previous Phase 1 trial of an aluminum phosphate adjuvanted Typhax formulation showed it induced Vi IgG after a single dose but that subsequent doses failed to further boost Vi IgG levels. The current study asked whether Advax-CpG adjuvant might instead be able to overcome polysaccharide-induced immune inhibition and improve Typhax immunogenicity. Advax-CpG adjuvanted Typhax elicited high and sustained Vi IgG responses in mice, rabbits and non-human primates (NHP) with levels being boosted by repeated immunization. High Vi antibody responses were lost in CD4 + T cell depleted mice confirming that despite the lack of conjugation of the polysaccharide to the carrier protein, Typhax nevertheless acts in a T cell dependent manner, explaining its ability to induce long-term B cell memory responses to Vi capable of being boosted. In NHP, Advax-CpG adjuvanted Typhax induced up to 100-fold higher Vi IgG levels than the commercial Typhim Vi polysaccharide vaccine. Typhax induced high and sustained serum bactericidal activity against S. Typhi and stimulated robust Vi IgG responses even in animals previously primed with a pure polysaccharide vaccine. Hence Advax-CpG adjuvanted Typhax vaccine is a highly promising candidate to provide robust and durable protection against typhoid fever.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Honda-Okubo Y, Cartee RT, Thanawastien A, et al. A typhoid fever protein capsular matrix vaccine candidate formulated with Advax-CpG adjuvant induces a robust and durable anti-typhoid Vi polysaccharide antibody response in mice, rabbits and nonhuman primates. Vaccine. 2022. PMID: 35750538. doi:10.1016/j.vaccine.2022.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。